Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907121 | 0.79 | ENPP3 (0.45) | ENPP3ENPP1SMPD3SLC40A1DYRK1A | |
| SCHEMBL23107319 | 0.77 | CCR1 (0.42) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL25590047 | 0.75 | PDE4A (0.31) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12913570 | 0.75 | PDE4A (0.31) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13482934 | 0.75 | NCF1 (0.37) | — | |
| SCHEMBL18510392 | 0.75 | ENPP3 (0.42) | ENPP3ENPP1DYRK1APDE4APDE4B | |
| SCHEMBL18510385 | 0.75 | ADORA2A (0.46) | DYRK1AGRM1PDE4APDE4BPDE4C | |
| SCHEMBL22815779 | 0.75 | ENPP3 (0.45) | ENPP3ENPP1SMPD3SLC40A1DYRK1A | |
| SCHEMBL22133200 | 0.72 | CYP1A2 (0.39) | ALDH1A1 | |
| SCHEMBL22133201 | 0.72 | SLC40A1 (0.38) | SLC40A1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023283595-A2 | INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220380762-A1 | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-12-01 | — | — | US | disclosed |
| US-20220002724-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20210388356-A1 | MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210238595-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2021102373-A1 | ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021087325-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2018098328-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APP, APBA1, PSEN1 | ENPP3 428/4885ENPP1 418/4885SMPD3 152/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | ENPP3 283/4885ENPP1 369/4885SMPD3 372/4885 |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | APP, APBA1, PSEN1 | ENPP3 428/4885ENPP1 418/4885SMPD3 152/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | ENPP3 1746/4885ENPP1 1650/4885SMPD3 1117/4885 |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | ENPP3 241/4885ENPP1 559/4885SMPD3 190/4885 |
| US-20220002724-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APP, APBA1, PSEN1 | ENPP3 428/4885ENPP1 418/4885SMPD3 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.